Loading
A phase 3 trial of Sacituzumab tirumotecan, Docetaxel, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) is a phase 3 interventional study registered as NCT06074588 by Merck Sharp & Dohme LLC, with 556 participants planned, started 2023-11-12 and due to reach its primary completion in 2027-05-10. Interventions recorded: Sacituzumab tirumotecan, Docetaxel, Pemetrexed. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Sacituzumab tirumotecan, EGFR-mutated non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Pemetrexed, Docetaxel, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.